Document Detail


Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
MedLine Citation:
PMID:  22786687     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Edoxaban (the former DU176b) an orally available direct factor Xa inhibitor has been engineered from DX-9065a, which was one of the first parenteral Xa inhibitors. Edoxaban has a time to peak plasma concentrations of 1-2 hours and a half-life of approximately 10 hours after multiple doses. Edoxaban is the third new oral anticoagulant in the group of direct factor Xa inhibitors that has gained clinical approval for the prevention of venous thromboembolism after major orthopaedic surgery. Currently, edoxaban is assessed in late stage clinical development for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (ENGAGE AF-TIMI 48, NCT00781391) and for the treatment and prevention of venous thromboembolism in patients with acute deep vein thrombosis and/or pulmonary embolism (HOKUSAI VTE, NCT00986154). Both clinical phase III trials represent the largest single clinical studies in their entity so far with an enrolment of 21107 patients in ENGAGE AF-TIMI 48 and a planned enrolment of 7500 patients in HOKUSAI VTE. The pharmacological properties of edoxaban will be discussed along with the current late stage clinical development focusing on the prevention of stroke and venous thromboembolism.
Authors:
I Ahrens; C Bode
Related Documents :
10641977 - Frequency, severity, and treatment of agitation in young versus elderly patients in the...
7290107 - Effect of corticosteroids on the thymus in myasthenia gravis.
11083507 - Tongue force in patients with myasthenia gravis.
6206447 - The rehabilitation of elderly paraplegic patients.
30197 - Alpha-blockers and urethral pressure in neurological patients.
23049297 - Analysis of oxidative status and biochemical parameters in adult patients with sickle c...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-12
Journal Detail:
Title:  Hamostaseologie     Volume:  32     ISSN:  0720-9355     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8204531     Medline TA:  Hamostaseologie     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Ingo Ahrens, MD, Heart Center Freiburg University, Hugstetter Str. 55, 79106 Freiburg, Germany, E-mail: ingo.ahrens@universitaets-herzzentrum.de.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Microarray comparative genomic hybridization and cytogenetic characterization of tissue-specific mos...
Next Document:  Direct Observation of Charge Transfer in Solid Electrolyte for Electrochemical Metallization Memory.